Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.73 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905098 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL5579187 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL4329512 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL8746346 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL5579185 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL4329518 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL16718910 | 0.99 | MEN1 (0.76) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL16718912 | 0.99 | MEN1 (0.76) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL10699234 | 0.96 | MEN1 (0.84) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL29926784 | 0.96 | MEN1 (0.84) | MEN1KMT2ALTB4R2ALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704797-A1 | OXYLIPINS IN THE TREATMENT OF SEBORRHEA | Pierre Fabre Dermo-Cosmétique (FR) | 2026-03-11 | — | — | EP | claimed |
| EP-4687496-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2026-02-11 | — | — | EP | claimed |
| US-20250248963-A1 | Inhibition Of Cellular Dysfunction And Cell Death With Deuterated Polyunsaturated Fatty Acids | BIOJIVA LLC | 2025-08-07 | — | — | US | claimed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | claimed |
| WO-2024227714-A1 | OXYLIPINS IN THE TREATMENT OF SEBORRHEA | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2024-11-07 | — | — | WO | claimed |
| WO-2024200855-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2024-10-03 | — | — | WO | claimed |
| EP-4437858-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2024-10-02 | — | — | EP | claimed |
| CN-118714935-A | Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment | 阿马里纳药物爱尔兰有限公司 | 2024-09-27 | — | — | CN | claimed |
| EP-4395759-A1 | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAS | Biojiva LLC (US) | 2024-07-10 | — | — | EP | claimed |
| CN-118201607-A | Methods, systems, and compositions for inhibiting cell dysfunction and cell death using deuterated PUFAs | 拜奥吉瓦有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | claimed |
| US-20230165824-A1 | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs | BIOJIVA LLC | 2023-06-01 | — | — | US | claimed |
| US-20230100267-A1 | INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED POLYUNSATURATED FATTY ACIDS | BIOJIVA LLC | 2023-03-30 | — | — | US | claimed |
| WO-2023034615-A1 | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAS | BIOJIVA LLC (US) | 2023-03-09 | — | — | WO | claimed |
| CN-115337401-A | Application of substance for inhibiting expression quantity and/or activity of lipoxygenase in reducing heart ischemia-reperfusion injury | 天津医科大学 | 2022-11-15 | — | — | CN | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20260144780-A1 | COMPOSITION FOR ENHANCING ADRENOMEDULLIN GENE EXPRESSION | HOUSE WELLNESS FOODS CORPORATION (JP) | 2026-05-28 | — | — | US | disclosed |
| US-6376688-B1 | Modified polyunsaturated fatty acids | PEPTIDE TECHNOLOGY LIMITED (AU) | 2002-04-23 | — | — | US | disclosed |
| EP-0869941-B1 | MODIFIED POLYUNSATURATED FATTY ACIDS | PEPTECH LTD (AU) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248963-A1 | Inhibition Of Cellular Dysfunction And Cell Death With Deuterated Polyunsaturated Fatty Acids | ALOX5, ALOX15, BAD | MEN1 4770/4885KMT2A 4718/4885LTB4R2 386/4885 |
| US-20230100267-A1 | INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED POLYUNSATURATED FATTY ACIDS | ALOX5, ALOX15, BAD | MEN1 4770/4885KMT2A 4718/4885LTB4R2 386/4885 |
| US-20230165824-A1 | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs | ALOX15, ALOX5, ALOX15B | MEN1 4305/4885KMT2A 4393/4885LTB4R2 204/4885 |
| US-20260144780-A1 | COMPOSITION FOR ENHANCING ADRENOMEDULLIN GENE EXPRESSION | TRPA1, TRPV1, TRPM6 | MEN1 2012/4885KMT2A 4803/4885LTB4R2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.